WCLC 2025 - Posters & ePosters-P3.12.14 Clinical Effectiveness and Safety of Tepotinib in Patients From Germany With MET Exon14 Skipping NSCLC: A Case Series

P3.12.14 Clinical Effectiveness and Safety of Tepotinib in Patients From Germany With MET Exon14 Skipping NSCLC: A Case Series

Back to course

Pdf Summary

This German case series evaluated the clinical effectiveness and safety of tepotinib, an oral MET tyrosine kinase inhibitor, in 25 patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Patients, aged 58–91 years (14 females, 15 with smoking history), received tepotinib through early access compassionate use programs between 2021 and 2022. Treatment lines varied from first to fourth, with a median duration of 5.6 months (range 0.8–41.9+ months). <br /><br />Efficacy outcomes, assessed by treating physicians, showed a partial response in 12 patients and stable disease in 9. Four patients treated for over 12 months demonstrated prolonged benefit. One notable case involved a 67-year-old female with stage IVB adenocarcinoma who remained on treatment for 41.9 months, maintaining partial response.<br /><br />The most frequent adverse event was edema, occurring in 17 patients (mostly Grades 1 and 2; three with Grade 3), managed conservatively with diuretics, compression stockings, and fluid restriction. Pleural effusion and fatigue were less common. Side effects led to dose reductions in six patients and permanent discontinuation in another six, mainly due to edema. No new safety concerns emerged.<br /><br />These real-world findings corroborate previous clinical trial data supporting tepotinib’s efficacy and manageable safety profile in METex14 skipping NSCLC. Treatment provided meaningful clinical benefit, including tumor shrinkage and durable responses, in a population with limited therapeutic options. The study highlights tepotinib as an effective treatment option post-immunotherapy and/or chemotherapy, expanding clinical evidence in routine practice across Germany.

Asset Subtitle

Frank Griesinger

Meta Tag

Speaker Frank Griesinger

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

tepotinib

MET exon 14 skipping mutation

non-small cell lung cancer

NSCLC

tyrosine kinase inhibitor

clinical effectiveness

safety profile

edema adverse event

compassionate use program

real-world evidence